462 related articles for article (PubMed ID: 19597027)
1. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
2. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.
Totani Y; Saito Y; Hayashi M; Tada T; Kohashi Y; Mieno Y; Kato A; Imizu H; Yoneda Y; Hoshino T; Uchiyama Y; Takeuchi Y; Okazawa M; Sakakibara H
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1181-5. PubMed ID: 19377885
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
Rinehart J; Adjei AA; Lorusso PM; Waterhouse D; Hecht JR; Natale RB; Hamid O; Varterasian M; Asbury P; Kaldjian EP; Gulyas S; Mitchell DY; Herrera R; Sebolt-Leopold JS; Meyer MB
J Clin Oncol; 2004 Nov; 22(22):4456-62. PubMed ID: 15483017
[TBL] [Abstract][Full Text] [Related]
12. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI
Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
Govindan R; Crowley J; Schwartzberg L; Kennedy P; Williams C; Ekstrand B; Sandler A; Jaunakais D; Bolejack V; Ghalie R
J Clin Oncol; 2006 Oct; 24(30):4848-54. PubMed ID: 17050870
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Reid T; Valone F; Lipera W; Irwin D; Paroly W; Natale R; Sreedharan S; Keer H; Lum B; Scappaticci F; Bhatnagar A
Lung Cancer; 2004 Sep; 45(3):381-6. PubMed ID: 15301879
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
Baka S; Ranson M; Lorigan P; Danson S; Linton K; Hoogendam I; Mettinger K; Thatcher N
Eur J Cancer; 2005 Jul; 41(11):1547-50. PubMed ID: 16026691
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
Miller AA; Herndon JE; Gu L; Green MR;
Lung Cancer; 2005 Jun; 48(3):399-407. PubMed ID: 15893009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
